Reviewing ContraFect Corporation (CFRX)’s and Sutro Biopharma Inc. (NASDAQ:STRO)’s results

This is a contrast between ContraFect Corporation (NASDAQ:CFRX) and Sutro Biopharma Inc. (NASDAQ:STRO) based on their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ContraFect Corporation N/A 0.00 48.38M -0.65 0.00
Sutro Biopharma Inc. 23.37M 10.17 49.17M -2.21 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of ContraFect Corporation and Sutro Biopharma Inc.

Profitability

Table 2 has ContraFect Corporation and Sutro Biopharma Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
ContraFect Corporation 0.00% -539.9% -113%
Sutro Biopharma Inc. -210.40% 0% 0%

Liquidity

7.2 and 7.2 are the respective Current Ratio and a Quick Ratio of ContraFect Corporation. Its rival Sutro Biopharma Inc.’s Current and Quick Ratios are 3.5 and 3.5 respectively. ContraFect Corporation has a better chance of clearing its pay short and long-term debts than Sutro Biopharma Inc.

Insider and Institutional Ownership

Roughly 57.6% of ContraFect Corporation shares are owned by institutional investors while 71.8% of Sutro Biopharma Inc. are owned by institutional investors. 7.63% are ContraFect Corporation’s share owned by insiders. Competitively, Sutro Biopharma Inc. has 8.5% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ContraFect Corporation -12.34% -6.79% 11.35% 11.35% 126.37% 103.96%
Sutro Biopharma Inc. 14.01% -8% 0% 0% 0% -21.32%

For the past year ContraFect Corporation had bullish trend while Sutro Biopharma Inc. had bearish trend.

Summary

ContraFect Corporation beats Sutro Biopharma Inc. on 5 of the 9 factors.

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.